Advertisement

Topics

AstraZeneca's Fasenra scores US approval in severe asthma

04:26 EST 15 Nov 2017 | Pharmafile

AstraZeneca and MedImmune, the company’s biologics research and development division, have revealed the decision by the FDA to approve Fasenra (benralizumab) in the US as an add-on treatment for severe asthma in patients over 12 with an eosinophilic phenotype.

read more

Original Article: AstraZeneca's Fasenra scores US approval in severe asthma

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Fasenra scores US approval in severe asthma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...